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Rationale: Enhanced production of reactive oxygen species (ROS), capable of reducing endog-
enous defense levels and enhancing inflammation, is suggested to play a role in sarcoidosis.
Antioxidant supplementation might offer protection against such ROS-mediated damage.
A promising candidate for antioxidant supplementation is the flavonoid quercetin.
Aim: To determine the antioxidant and inflammatory status in sarcoidosis. Furthermore, the
potential of quercetin to mitigate the occurring inflammation will be assessed.
Methods: Non-smoking sarcoidosis patients and healthy controls matched for age, gender and
dietary behavior were enrolled (NCT-00512967). Measurements included assessment of total
plasma antioxidant capacity, vitamin C, uric acid, glutathione, basal and LPS-induced levels
of tumor necrosis factor alpha (TNFa), interleukin (IL)-8 and -10 as well as the effect of quer-
cetin on these levels.
Results: Compared to their controls, the sarcoidosis patients displayed significantly lower total
plasma antioxidant capacity, decreased levels of vitamin C, uric acid and glutathione
and increased levels of basal TNFa and IL-8. Quercetin significantly decreased ex vivo LPS-
induced TNFa- and IL-8 production in a concentration-dependent manner in both groups. Inter-
estingly, this quercetin effect was more pronounced in sarcoidosis patients.
Discussion: The endogenous antioxidant defense was significantly reduced in sarcoidosis, indi-
cating that oxidative stress underlies the pathology of this disease. Furthermore, the inflam-
matory status was significantly enhanced in sarcoidosis. Finally, our results regarding the
effect of quercetin on cytokine production imply that sarcoidosis patients might benefit fromof Pharmacology and Toxicology, Faculty of Medicine, Maastricht University, Universiteitssingel 50,
e Netherlands. Tel.: þ31 43 388 1340; fax: þ31 43 388 4149.
unimaas.nl (A.W. Boots).
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Antioxidant and inflammatory status in sarcoidosis 365antioxidant supplementation not only by empowering the relatively low protection against ROS
but also by reducing inflammation.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is an interstitial lung disease which incidence
varies among different countries over the world. In Scan-
dinavian countries the incidence is higher compared to
more southern countries.1 In The Netherlands and Germany
it is estimated that the incidence is approximately 20e25
per 100,000 inhabitants.1
Sarcoidosis is an antigen-driven, multisystem, granu-
lomatous disorder of which the exact etiology is
unknown.2,3 Current evidence supports the concept that
the pathogenesis of sarcoidosis involves a highly polar-
ized T-helper 1 immune response to pathogenic tissue
antigens or specific environmental factors.1 Granuloma
formation is regulated by a complex interaction between
T-helper lymphocytes and macrophages, in which cyto-
kines such as tumor necrosis factor (TNF)-a play an
important role.2
Enhanced formation of reactive oxygen species (ROS) is
suggested to play a role in the pathogenesis of sarcoido-
sis.4e6 However, little is known about the endogenous
defense levels present in sarcoidosis, i.e. the antioxidant
levels that can offer protection against ROS-mediated
damage. This prompted us to determine the endogenous
antioxidant levels present in sarcoidosis patients. It is
expected that the high production of ROS that occurs in
sarcoidosis will consume antioxidants, thereby reducing
their levels. As a result, antioxidant supplementation might
be beneficial in sarcoidosis treatment.
ROS are also capable of initiating and mediating
inflammation in the lung.7,8 Besides enhanced ROS forma-
tion, inflammation plays a key-role in the occurrence and
progression of sarcoidosis too.9,10 Conventional treatment
is focused on attenuating granuloma formation with drugs
that inhibit antigen presentation or with non-specific anti-
inflammatory agents such as glucocorticosteroids, metho-
trexate, or azathioprine.2 However, all these therapies fail
to be completely efficacious.11,12 Strengthening the
endogenous antioxidant defense with antioxidant supple-
mentation, and thereby decreasing the levels of ROS
production and ROS-mediated damage, might mitigate the
elevated inflammation present.
The past few years, much attention has been given to
the potential health-beneficial properties of flavonoids,
natural occurring polyphenolic compounds, and to quer-
cetin, the most commonly occurring flavonoid, in partic-
ular. Quercetin is an extremely powerful antioxidant13 and
therefore it is tempting to speculate that quercetin can
exert positive effects in sarcoidosis.
The aim of the present study is to determine both the
antioxidant and inflammatory status in sarcoidosis.
Furthermore, the potential anti-inflammatory effects of
antioxidants, exemplified with the flavonoid quercetin, will
be assessed in this disease. To this extent, cytokineproduction will be evoked ex vivo by lipopolysaccharide
(LPS), a patho-physiological relevant stimulator of mono-
cytes, neutrophils and B lymphocytes.14e17
Materials and methods
Chemicals
Quercetin and lipopolysaccharide (LPS, E. coli 0.26:B6)
were purchased from Sigma Chemical Co. (St. Louis, USA).
RPMI 1640 medium containing L-glutamine was obtained
from Gibco (UK). Human TNFa (7300 pg/ml), human IL-10
(4000 pg/ml) and human IL-8 (10 ng/ml) were acquired
from CLB/Sanquin (Amsterdam, The Netherlands). All other
chemicals were of analytical grade.
Methods
Participants
General information
All participating patients were recruited from the patients
visiting the out-patient clinic of the university hospital
Maastricht, a tertiary referral for The Netherlands. The
sampling took place at the day they had to come in for
a regular check-up. Based on food questionnaires, all
patients had comparable dietary habits with an average
daily intake of quercetin of approximately 15 mg. None of
the participants used any vitamin or food supplementation.
The Medical Ethical Committee of Maastricht University
and the University Hospital Maastricht had approved the
protocol before the beginning of the study and the study
was registered at http://www.clinicaltrials.gov (NCT-
00512967). All participants were fully informed about the
aim and details of the study and have given their written
informed consent.
Sarcoidosis patients
Twenty-one non-smoking patients with symptomatic
sarcoidosis (age 44  1) were enrolled in this study.
Patients had been diagnosed with sarcoidosis based on
clinical features, together with bronchoalveolar lavage
(BAL) fluid analysis results (data not shown).18 Moreover, 17
out of the 20 sarcoidosis patients had a transbronchial
biopsy confirmation of the disease. The clinical symptoms
of all patients included respiratory symptoms, i.e. dyspnea,
coughing and chest pain. The characteristics of the studies
population are summarized in Table 1. According to their
chest radiographic stage, patients were subdivided into two
groups, i.e. mild (stage 0e1) and severe sarcoidosis (stage
2e4). In the sarcoidosis patients, both the DLCO (80  3%)
and the FEV1 (84  6%) were reduced. This reduction in
FEV1 and DLCO was even more pronounced in stage 4
sarcoidosis patients compared with the other sarcoidosis
Table 1 Characteristics of the participants.
Sarcoidosis Controls
Number (m/f) 20 (16/4) 11 (7/4)
Age 31e60 (44  1) 40e58 (48  3)
Length 158e194 (177  2) 162e188 (175  3)
Weight 52e107 (80  4) 59e95 (77  3)
Body mass index 18.5e31 (25  1) 18.5e30 (26  1)
Time since diagnosis 0e30 (5  2) e
Biopsy taken Yes:17 No:3 e
DLCO 39e107 (80  3) 90e110
FEV1 42e135 (84  6) 90e110
FVC 49e152 (92  6) 90e110
Chest radiograph
stage 0/I/II/III/IV
(n)
1/4/9/2/4 e
Controls are matched on age and gender and do therefore not
significantly differ from the patients regarding these parame-
ters. Age is expressed in year, length in cm, weight in kg, and
both DLCO (diffuse capacity of the lung for carbon monoxide)
and FEV1 (forced expiratory volume in 1 s) in % of the predicted
value based on age and gender. Data are expressed as range
(mean  SEM).
366 A.W. Boots et al.patients (52  10% (nZ 4) vs 91  5% (nZ 16) and 60  4%
(nZ 4) vs 83  3% (nZ 16) respectively). With regards to
the FVC, only stage 4 patients displayed lower levels than
the other sarcoidosis patients, but on average this lung
function parameter did not differ considerably from the
control range. This lack of major differences in FVC,
a reliable indicator of disease progression and pulmonary
function loss, suggests that lung function in the sarcoidosis
group and the healthy controls is comparable.
At the moment this study was performed, none of the
sarcoidosis patients used any medication.
Controls
The control group consisted of 11 non-smoking healthy
volunteers, all with dietary habits comparable to those of
the patients and a quercetin intake of approximately 15 mg
per day. All controls did not use any medication or vitamin/
food supplementation.
Lung function measurement
Lung function measurements included FEV1, DLCO and FVC.
FEV1 and FVC were measured with a pneumotachograph,
DLCO by the single-breath method (Masterlab, Jaeger,
Wu¨rzburg, Germany). Values were expressed as
a percentage of those predicted based on age and gender.19
Preparation of blood samples
Blood was collected from all participants in EDTA-containing
vacutainer tubes (Vacutainer, Becton-Dickinson) and kept on
ice prior to processing which occurred within 1 h after blood
collection. Blood was aliquoted into eppendorfs for both the
ascorbic acid and the GSH/GSSG analysis: for the former 10%
TCAwasadded to thewholeblood,whereas1.3%SSA in10 mM
HCl was used to preserve the samples for the latter. Anotheraliquot of bloodwas used for the incubations required for the
blood-based cytokine production assay as described in that
section below. The remaining blood was centrifuged
(3000 rpm,50 at4 C) toobtainplasma.Deproteinizationofan
ailquot of this plasma, using 10% TCA (1:1) followed by
centrifugation (13,000 rpm, 50 at 4 C), was carried for the
trolox equivalent antioxidant capacity measurement. All
samples were stored at 80 C prior to analysis.
Antioxidant status
The antioxidant status was evaluated by measuring the
total plasma antioxidant status as well as the plasma levels
of the individual antioxidants ascorbic acid, uric acid and
glutathione.
Trolox equivalent antioxidant capacity
The trolox equivalent antioxidant capacity (TEAC value) is
a measurement for the total antioxidant status, relating
the free radical scavenging properties of a solution or
a compound to that of the synthetic antioxidant trolox. The
assay is performed as previously described20 with minor
modifications. In short, an ABTS$ solution was prepared
freshly by mixing 23 mM ABAP with 2.24 mM ABTS2 stock
solution in 100 mM phosphate buffer (pH 7.4). This solution
washeatedat70 C forapproximately 10 min.Toevaluate the
ABTS$ formation, theabsorbanceat734 nmwasdetermined
every 2e3 min. At a absorbance between 0.6 and 0.7 the
reaction was stopped by cooling the ABTS$ solution on ice.
To measure the antioxidant capacity of the samples,
50 ml of the deproteinated sample was mixed with 950 ml of
37 C ABTS$ solution and pre-incubated for 20 s at 37 C.
Absorbance was then measured at 734 nm and related to
the absorbance of trolox to calculate the trolox equivalent
of the samples.20
Ascorbic acid measurement
Calibrators were prepared freshly, containing the same
amount of TCA as the samples. Samples and calibrators
were processed identically.21
All samples were centrifuged (5000 rpm, 100 at 4 C)
after which the supernatant was added to a 4.5 M sodium-
acetate buffer (pH 6.2), containing an ascorbate oxidase
spatula, and incubated for 5 min at 37 C. Subsequently,
the spatula was removed and 0.1% (w:v) OPDA was added.
After mixture the samples were incubated for 30 min at
37 C. Afterwards, the samples were injected in the HPLC
system. HPLC analysis of the samples was performed using
a Hypersil BDS column (125 mm  2 mm). The column was
eluted isocratically with eluens containing 20% methanol
and 80% potassium phosphate buffer using 355 nm as exci-
tation and 425 nm as emission wavelength. The ascorbic
acid content of each sample was quantified using the
calibrators.21
Uric acid measurement
Uric acid was measured in the plasma of all samples as
described previously.22 To this extent an aliquot of
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Figure 1 Antioxidant status in sarcoidosis patients (nZ 20)
compared to that in their matched controls (nZ 11). The
values representing the levels of the various parameters in the
patient group are connected to form the dark gray area
whereas the light gray area reflects the same in the control
group. Total plasma antioxidant status (TEAC) is expressed in
Trolox equivalent (mM), vitamin C and uric acid in mM and both
GSH and GSSG in mM/mg Hb. All axes have a linear scale. The
origin is zero. The value at the end of the axes is indicated by
the number depicted there. Data are expressed as mean -
 SEM; *Z P < 0.03 vs the matched controls. The TEAC value
of sarcoidosis patients is significantly lower than that of their
matched controls (535  21 mM vs 652  21 mM). The levels of
individual antioxidants, i.e. uric acid, glutathione and vitamin
C, are also significantly reduced in the patient group compared
to the controls (respectively 185  16 mM vs 324  15 mM;
8.2  0.6 mM vs 13  1.9 mM; 52  4 mM vs 65  4 mM).
Antioxidant and inflammatory status in sarcoidosis 367deproteinated plasma was injected in the HPLC system with
fluorescent detection. HPLC analysis of the samples was
performed using a Hypersil BDS column (125 mm  4 mm).
The column was eluted isocratically with a 5 mM sodium
phosphate buffer (pH 3.3) using 250 nm as excitation and
410 nm as emission wavelength. The uric acid content of
each sample was quantified using calibrators with known
levels of uric acid.
GSH, GSSG and hemoglobin measurement
Both GSH and GSSG calibrators were prepared freshly and
contained the same concentrations of SSA as the samples.
Samples and calibrators were treated identically.23
All samples were centrifuged (5000 rpm, 100 at 4 C)
after which the supernatant was collected. For the GSH
measurement, an aliquot of the supernatant of each
sample was added (1:1) to pre-heated 0.6 mM DTNB
(37 C) and incubated for 15 s (37 C), after which the
absorbance of the sample was measured at 412 nm. For
the GSSG measurement, an aliquot of the supernatant of
each sample was added to 2-vinyl-pyridine (10:1) and
incubated for 1 h at room temperature. Subsequently,
the supernatant was added (1:9) to a mixture of 0.6 mM
DTNB and 0.8 mM NADPH (37 C) and the reaction was
started by adding the enzyme glutathione reductase
(1:20). The absorbance of the sample was measured for
3 min at 412 nm. Both the GSH and GSSG content of each
sample were quantified using calibrators and related to
the hemoglobin content. Hemoglobin content was
determined by preparing hemolysates of each sample by
adding blood to milliQ (1:1). After diluting these hemo-
lysates 20 times, each sample was added to an equal
volume of Drabkins reagens, vortexed thoroughly and
incubated 15 min at room temperature. Subsequently,
the absorbance of each sample was measured at 540 nm
and hemoglobin contents were quantified using appro-
priate standards.23
Inflammatory status
Both basal and LPS-induced levels of the selected cytokines
were quantified using PeliKine Compact human ELISA kits
(CLB/Sanquin, The Netherlands). Consequently, the LPS-
induced cytokine production assay was performed priory.
LPS-induced cytokine production assay
Within 1 h after blood collection, the blood-based cytokine
production assay was performed as described previ-
ously.15,24 To this end, blood was aliquoted into 24-well
sterile plates and diluted 1:4 with RPMI 1640 (supple-
mentend with L-glutamine). Subsequently, pre-incubation
of the diluted blood with quercetin (0, 1, 3 and 30 mM dis-
solved in 0.5% ethanol) was performed for 30 min. After-
wards, 0.1 ng/ml LPS was added to induce cytokine
production. After this stimulation, the plates were incu-
bated for 24 h at 37 C in 5% CO2. Cell-free supernatant
fluids were then collected by centrifugation (6000 rpm, 100
at 4 C) and stored at 20 C prior to analysis. All incuba-
tions were performed in triplicate.ELISA measurement
All cytokines were quantified using PeliKine Compact human
ELISA kits (CLB/Sanquin, The Netherlands) based on appro-
priate and validated sets of monoclonal antibodies. Assays
were performed as described in the manufacturer’s
instructions. Cytokine production was related to that of the
control incubation without quercetin. The ethanol (0.5%)
used to dissolve quercetin did not show any influence on the
ex vivo LPS-induced cytokine production (data not shown).
Statistics
The data of both the patient groups and their matched
controls were compared using a Wilcoxon’s signed rank
test. A two-tailed probability value (P-value) equal to or
less than 0.05 was considered to be statistically significant.
Results
All antioxidant parameters measured were decreased in the
blood from sarcoidosis patients (Fig. 1) compared to the
antioxidant-levels of their age-, gender- and dietary
behavior matched controls.
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Figure 2 Basal (panel A) as well as LPS-induced levels (panel
B) of TNFa, IL-8 and IL-10 in sarcoidosis patients (nZ 20)
compared to their matched controls (nZ 11). Basal TNFa and
IL-8 levels are both significantly higher in the patient group
compared to their matched controls (TNFa: 22  2 pg/ml vs
5  0.3 pg/ml; IL-8: 12.3  1.7 pg/ml vs 7.9  0.4 pg/ml).
Basal IL-10 levels are unaltered in the patients compared to
their matched controls (2.2  0.2 pg/ml vs 2.1  0.2 pg/ml).
LPS-induced TNFa and IL-8 levels are both significantly higher
in the patients than in the controls. LPS-induced IL-8 levels are
approximately eight times higher than the LPS-induced TNFa
and IL-10 levels. Data are expressed as mean  SEM; *P  0.01
vs the matched controls for panel A; *P < 0.04 vs the matched
controls for panel B.
368 A.W. Boots et al.Reduced glutathione (GSH) was significantly declined in
the blood of sarcoidosis patients compared to the GSH-level
in matched controls (25% decline). Glutathione disulphide
(GSSG) levels, that are relatively low because of the effi-
cient reduction of GSSG by endogenous glutathione reduc-
tase, did not significantly differ between the patient and
control group.
The total plasma antioxidant capacity, i.e. the total sum
of all plasma antioxidants that is expressed as Trolox
equivalent, was in sarcoidosis patients approximately 75%
of that of the matched controls.
Two endogenous antioxidants that are known to
contribute substantially to the total plasma antioxidant
status are uric acid and vitamin C. Uric acid levels as well
as vitamin C levels were significantly declined in the
plasma of sarcoidosis patients (to respectively 60% and
79% of the control levels) compared to their matched
controls.
Basal levels of both TNFa and IL-8 (Fig. 2A), two pro-
inflammatory cytokines, were significantly increased in
patients suffering from sarcoidosis compared to their
controls. Basal levels of the anti-inflammatory cytokine IL-
10 were not different between the sarcoidosis patients and
the matched controls (Fig. 2A). As a result, the ratios of the
pro- vs the anti-inflammatory cytokines TNFa/IL-10 and IL-
8/IL-10 were also significantly increased in the sarcoidosis
patients.
The LPS-induced TNFa and IL-8 levels (Fig. 2B) found in
the sarcoidosis group were significantly higher compared to
the controls, whereas IL-10 production was similar in both
groups after LPS stimulation (Fig. 2B).
The flavonoid quercetin significantly reduced the TNFa
(Fig. 3A) and IL-8 production (Fig. 3B), induced in blood by
LPS, in the sarcoidosis group as well as in their matched
controls. The extent of this reduction depended on: (i) the
quercetin concentration (Fig. 3); and (ii) the cytokine
production induced by LPS without quercetin (Fig. 4). The
slopes of the fits depicted in Fig. 4 indicate that both
cytokines responded more sensitive (50% for IL-8 and 80%
for TNFa) to quercetin in the sarcoidosis group compared
to the matched controls (Figs. 4A,B). The IL-10 production,
induced in blood by LPS, of both patients and controls was
not affected by quercetin (Fig. 3C). As a result, the ratios
of the pro- vs the ant-inflammatory cytokines TNFa/IL-10
and IL-8/IL-10 were also significantly reduced by the
flavonoid.
Antioxidant as well as cytokine levels did not display
significant differences between the two sexes. No differ-
ence was found between the mild (stage 0e1, nZ 5) and
severe (stage 2e4, nZ 15) form of sarcoidosis regarding
the residual plasma antioxidant capacity or the GSSG, uric
acid, vitamin C, basal IL-8 and basal IL-10 levels. Compared
to the mild form of sarcoidosis, the severe form showed
a trend towards decreased GSH levels (6.8  1.1 mM
(nZ 15) vs 7.6  1.3 mM (nZ 5); P < 0.35), a decreased
total plasma antioxidant capacity (519  19 mM (nZ 13) vs
533  30 mM (nZ 5); P < 0.25) and increased TNFa levels
(24  3 pg/ml (nZ 15) vs 19  3 pg/ml (nZ 5); P < 0.28).
Stage 4 sarcoidosis patients displayed a significant lower
total plasma antioxidant capacity compared to the other
sarcoidosis patients (473  15 mM vs 543  23 mM;
P  0.05).Discussion
The role of enhanced ROS production has been implicated
in the pathology of sarcoidosis,4,5 but the influence of this
increased ROS formation on the endogenous antioxidant
levels in sarcoidosis have not yet been reported. To the best
of our knowledge, this study is the first that demonstrates
a significant decrease in the total plasma antioxidant
capacity as well as in the blood levels of the important
endogenous antioxidants glutathione, vitamin C and uric
acid in sarcoidosis patients compared to healthy controls
matched for age, gender and dietary behavior. The severe
form of sarcoidosis displays a trend towards a lower total
plasma antioxidant capacity as well as a lower GSH level,
indicating that the severity of the disease might be related
to the level of oxidative stress occurring.
The patients and controls were matched for their dietary
behavior, indicating that the observed decreased
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Antioxidant and inflammatory status in sarcoidosis 369antioxidant levels are not the result of a different dietary
intake. The lower endogenous antioxidant defense found,
therefore, confirms the elevated production of ROS present
in sarcoidosis. Low endogenous antioxidant levels combined
with enhanced ROS formation is defined as oxidative stress.
Oxidative stress can cause serious oxidative damage to
biological macromolecules like DNA, lipids and proteins.25
Several studies have shown that the levels of biomarkers
of oxidative damage, i.e. exhaled ethane4 and both 8-iso-
prostane26 and oxidized proteins27 in the bronchoalveolar
lavage fluid (BALF), are indeed increased in sarcoidosis
patients of different clinical stages. Furthermore, the
transcription factor NF-kB, of which it is known that it is
activated by radical damage, is increased in alveolar
macrophages28 and mononuclear blood cells29 of active
sarcoidosis patients compared to those of healthy controls.
To strengthen the endogenous antioxidant defense and
thus offer more protection against ROS, antioxidant
supplementation seems a logical strategy in the treatment
of sarcoidosis. Moreover, antioxidant supplementation
might not only protect against ROS-mediated damage, it
might also mitigate elevated inflammation since ROS can
enhance inflammation. ROS are capable of promoting
inflammation in the lung by activating transcription factors
like NF-kB and activator protein-1 that induce pro-inflam-
matory cytokines and chemokines.7,8 In vitro studies, using
both macrophages and alveolar and bronchial epithelial
cells, have demonstrated that oxidants can indeed initiatethe production of inflammatory mediators like IL-8 and
NO$.30 Because of this relation between ROS and inflam-
matory processes, the inflammatory status was also evalu-
ated in sarcoidosis patients. To this end, basal levels of the
pro-inflammatory cytokines TNFa and IL-8 and the anti-
inflammatory cytokine IL-10 were measured.
TNFa was chosen since it is suggested to be the most
prominent cytokine present in sarcoidosis.2,31 TNFa has
been shown to play a pivotal role in the granuloma forma-
tion occurring in sarcoidosis.2 Furthermore, the individual
capability of a patient to release TNFa is suggested to be
linked to the progression of the disease, thereby linking this
cytokine to the pathogenesis of sarcoidosis.32 TNFa is
capable of activating transcription factors NF-kB and AP-1
that subsequently will further enhance other inflammatory
mediators such as IL-8.8,33 and TNFa itself, thereby ampli-
fying the TNFa-mediated inflammatory effects.
Our study shows that basal TNFa-levels are significantly
enhanced in sarcoidosis patients compared to healthy
controls. This finding is in line with previous studies.34,35
The severe form of sarcoidosis tends to display higher TNFa
levels, indicating that the severity of the disease might be
related to the level of inflammation occurring. It has been
reported that conventional therapy with glucocorticoids
fails to be completely efficacious in all sarcoidosis patients
and that this therapy, for instance, does not reduce the
enhanced NF-kB activity found in sarcoidosis patients.29
Recently, alternative strategies using anti-TNFa agents
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values (nZ 20 for the patients; nZ 11 for the controls).
370 A.W. Boots et al.have been reported to have some clinical beneficial
effects.36 For example, Baughman et al have recently
shown not only that anti-TNFa therapy significantly
improves the predicted FVC of sarcoidosis patients after
24 weeks, but also that patients with more severe disease
tend to benefit more from this treatment.37
The finding that basal IL-8 levels are significantly
increased in sarcoidosis indicates that this cytokine is also
involved in the enhanced inflammatory processes present in
this disease. This is again in line with previous studies,
which show an increased expression of IL-8 in sarcoid-
osis.2,38,39 It should be noted that IL-8 can also be induced
by TNFa and that the higher IL-8 level might reflect the
higher TNFa level.
No changes were found in the basal levels of anti-
inflammatory cytokine IL-10 between the sarcoidosis and
control group. The results of previous studies on this cyto-
kine are conflicting. Some studies report enhanced IL-10levels in the broncho-alveolar lavage fluid (BALF) of
sarcoidosis patients as a compensatory mechanism,38,39
whereas other studies fail to demonstrate this increase.40,41
To determine the anti-inflammatory potential of anti-
oxidants, the effect of quercetin on LPS-induced produc-
tion of TNFa, IL-8 and IL-10 was quantified in blood. The
employed model, unlike models using isolated cells or
cultured cells grown in medium, represents a more physi-
ological and well reproducible model to measure cytokine
production ex vivo.15,42 The natural cell-to-cell interactions
are preserved and all blood components are present in in
vivo ratios with non-cellular components, resulting in
a system that reflects the in vivo condition well.15,42
In both the sarcoidosis and the control group, the anti-
oxidant quercetin significantly reduces the LPS-induced
TNFa and IL-8 production, whereas the LPS-induced IL-10
production is not significantly altered by the flavonoid. The
inhibitory effect of quercetin on both anti-inflammatory
cytokines is dose-dependent and could already be achieved
at an in vivo attainable concentration of 1 mM.43 Interest-
ingly, the reduction in cytokine levels by quercetin is more
pronounced in sarcoidosis patients compared with their
matched controls. This finding is in agreement with our
previous study which showed that quercetin did not display
major anti-inflammatory effects in vivo or ex vivo in the
blood of healthy volunteers.24
The anti-inflammatory actions of quercetin observed in
the present study could very well be related to its anti-
oxidativeactivity. This associationbetween theantioxidative
and anti-inflammatory capabilities of flavonoids has also
been suggested in several in vitro44,45 and in vivo studies.46,47
The reduced antioxidant status may also be involved in the
differences observed between the sarcoidosis patients and
their matched controls regarding both: (i) the significantly
higher TNFa and IL-8 production induced by LPS; and (ii) the
more pronounced effect of quercetin herein. Therefore,
sarcoidosis patients may benefit from the use of antioxidant
supplementation. The fact that quercetin is a dietary anti-
oxidant indicates that the diet is an important factor in
sarcoidosis. However, the toxicity of quercetin should be
carefully evaluated especially when it is chronically admin-
istered.48,49 Clinical studies are needed to substantiate the
efficacy as well as the safety of quercetin supplementation.
In conclusion, our study shows for the first time that the
endogenous antioxidant levels as well as the total plasma
antioxidant capacity are significantly reduced in sarcoid-
osis, emphasizing that severe oxidative stress underlies the
pathology of this disease. Moreover, inflammation is
enhanced in sarcoidosis as shown by the increased basal
levels of the pro-inflammatory cytokines TNFa and IL-8. The
antioxidant quercetin shows ex vivo significant anti-
inflammatory effects in both sarcoidosis patients and
controls that are, interestingly, more pronounced in the
first group. Probably, this larger anti-inflammatory effect of
the flavonoid in sarcoidosis is associated with the compro-
mised antioxidant status present in these patients. This
suggests that particularly in sarcoidosis patients empow-
ering the antioxidant defense system with alimentary
antioxidants, such as quercetin, might be fruitful. This is
especially important since it has been reported that
conventional treatment with glucocorticoids is not effica-
cious in all sarcoidosis patients.
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